Cargando…

GOALs in relapsed DLBCL

Detalles Bibliográficos
Autores principales:	Rösler, Wiebke, Zenz, Thorsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9544586/ https://www.ncbi.nlm.nih.gov/pubmed/35695285 http://dx.doi.org/10.1111/bjh.18296

Ejemplares similares

American Society of Hematology 2020 Podcast Collection: FL and DLBCL
por: Fox, Christopher Paul, et al.
Publicado: (2021)

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
por: Hawkes, Eliza A., et al.
Publicado: (2021)

Relapse timing is associated with distinct evolutionary dynamics in DLBCL
por: Hilton, Laura K., et al.
Publicado: (2023)

Goals of goal-directed sedation
por: Shehabi, Yahya
Publicado: (2015)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL
por: Torka, Pallawi, et al.
Publicado: (2022)

Leptomeningeal relapse in primary cutaneous DLBCL: Implications for a prophylactic CNS therapy
por: Sundriyal, Deepak, et al.
Publicado: (2020)

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
por: Zhang, Jing, et al.
Publicado: (2023)

Inotropes in goal-directed therapy: Do we need 'goals'?
por: Futier, Emmanuel, et al.
Publicado: (2010)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

Goal-directed or goal-misdirected - how should we interpret the literature?
por: Roche, Anthony M, et al.
Publicado: (2010)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum
por: Greenawalt, Danielle M., et al.
Publicado: (2017)

Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab
por: Madabhavi, Irappa, et al.
Publicado: (2019)

Check'-ing DLBCL
por: Salaverria, Itziar, et al.
Publicado: (2015)

DLBCL Coast to Coast
por: Tesio, Melania
Publicado: (2018)

Before Sustainable Development Goals (SDG): why Nigeria failed to achieve the Millennium Development Goals (MDGs)
por: Oleribe, Obinna Ositadimma, et al.
Publicado: (2016)

Computational Goals, Values and Decision-Making
por: Dennis, Louise A.
Publicado: (2020)

Rethinking the Goals of Diabetes Prevention Programs
por: Mezuk, Briana, et al.
Publicado: (2021)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL
por: Liu, Hui, et al.
Publicado: (2020)

Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patients
por: Tokola, Susanna, et al.
Publicado: (2020)

Extranucleolar CYCLON Staining Pattern Is Strongly Associated to Relapse/Refractory Disease in R-CHOP–treated DLBCL
por: Bouroumeau, Antonin, et al.
Publicado: (2021)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

“Early goal-directed therapy” versus “Early” and “goal-directed” therapy for severe sepsis and septic shock: Time to rationalize
por: Dhooria, Sahajal, et al.
Publicado: (2015)

Toward protein-energy goal-oriented therapy?
por: Singer, Pierre
Publicado: (2009)

Reducing stunting in Bhutan: an achievable national goal
por: Dzed, Laigden, et al.
Publicado: (2016)

Assistive products and the Sustainable Development Goals (SDGs)
por: Tebbutt, Emma, et al.
Publicado: (2016)

Clinical Goals and Barriers to Effective Psoriasis Care
por: Strober, Bruce E., et al.
Publicado: (2018)

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

Successful bridging therapy with tirabrutinib before ASCT for relapsed primary DLBCL of the CNS complicated with PBC, cirrhosis, and pancytopenia
por: Nakagawa, Noriharu, et al.
Publicado: (2022)

Millennium Development Goals 4 and 5: progress and challenges
por: Bryce, Jennifer, et al.
Publicado: (2013)

Moving towards the goals of FP2020 — classifying contraceptives()
por: Festin, Mario Philip R., et al.
Publicado: (2016)

Geography’s contribution to the Sustainable Development Goals: Ambivalence and performance
por: Nightingale, Andrea J
Publicado: (2018)

Adapting the Goal Attainment Approach for Major Depressive Disorder
por: McCue, Maggie, et al.
Publicado: (2019)

Investing in the Sustainable Development Goals: Mobilization, channeling, and impact
por: Zhan, James X., et al.
Publicado: (2021)

Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
por: Harrysson, Sara, et al.
Publicado: (2021)

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set
por: Vrabac, Damir, et al.
Publicado: (2021)

Should we modulate the neonatal microbiome and what should be the goal?
por: van Best, Niels, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4asdb4d5oc6jvaspq1idb5utm0